MedTrace Logo

FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma

NCT01410630 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 66

Last updated 2021-05-11

No results posted yet for this study

Summary

A research study of a new method of visualizing internal organs called 18F-FLT PET/CT that yields better tracking of cancer treatment progress. PET/CT stands for positron emission tomography with low dose computed tomography and has been used for many years. 18F-FLT PET/CT uses a new tracer, fluorothymidine, which is taken up by cells that are actively proliferating or dividing such as cancer cells. We hope to learn whether this tracer is superior to the conventional tracer for monitoring treatment of diffuse large B-cell lymphoma (DLBCL).

Conditions

  • Lymphoma
  • Lymphoma, Non-Hodgkin
  • Large B Cell Diffuse Lymphoma

Interventions

DIAGNOSTIC_TEST

FLT-PET/CT

Standard of Care

DIAGNOSTIC_TEST

FDG-PET/CT

Standard of Care

DRUG

FLT

5 mCi IV

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Jonsson Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Andrew Quon, MD · University of California at Los Angeles

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-07
Primary Completion
2019-10-04
Completion
2019-10-04

Countries

  • United States
  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01410630 on ClinicalTrials.gov